Andere talen BioRestorative Therapies, Inc.

Aandelen

BRTX

US0906556065

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 08-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,42 ^USD	-3,40%		0,00%	-18,39%

08/05	BioRestorative Therapies, Inc. verbetert preklinisch metabolisch programma met een nieuw, op exosomen gebaseerd biologisch geneesmiddel dat gericht is op obesitas	CI
30/04	BioRestorative Therapies, Inc. kondigt een transformerende commerciële overeenkomst aan met Cartessa Aesthetics, LLC	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity	08/05
BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity	08/05
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	30/04
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology	30/04
BioRestorative Therapies, Inc. Announces Transformative Commercial Agreement with Cartessa Aesthetics, LLC	30/04
BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment	16/04
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial	16/04
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	16/04
BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	16/04
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	08/04
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	08/04
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants	03/04
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K	01/04
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference	11/03
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting	14/02
Top Midday Decliners	06/02
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market	06/02
Top Premarket Decliners	06/02
BioRestorative Therapies Reports Positive Results From Lumbar Disc Treatment Candidate Trial; Shares Rise	05/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioRestorative Therapies, Inc.

Aandelen

BRTX

US0906556065

Andere talen

Filters